<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02279693</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A00122-45</org_study_id>
    <nct_id>NCT02279693</nct_id>
  </id_info>
  <brief_title>Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer</brief_title>
  <acronym>PROSTRACK</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the dose received by the prostate with in vivo dosimetry when delivering
      image guided radiation therapy (IGRT) associated with intensity modulated radiation therapy
      (IMRT) for patients with localized prostate cancer using two repositioning techniques:
      fiduciary markers or soft tissues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      10 participants will receive a cone beam computed tomography (CBCT) repositioning, while the
      other 10 will receive a kV imaging of fiducial marker repositioning. The principal objective
      is to evaluate and compare the dose received by the prostate using two repositioning
      techniques.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date type="Actual">December 22, 2014</start_date>
  <completion_date type="Anticipated">January 21, 2020</completion_date>
  <primary_completion_date type="Actual">December 22, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dosimetry (measurement of the absorbed dose, delivered to prostate, by ionizing radiation)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>CBCT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>cone beam computed tomography (CBCT) repositioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fiducial markers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>kV imaging of fiducial marker repositioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CBCT</intervention_name>
    <description>10 participants will receive a cone beam computed tomography (CBCT) repositioning</description>
    <arm_group_label>CBCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fiducial marker (kV imaging)</intervention_name>
    <description>10 participants will receive a kV imaging of fiducial marker repositioning.</description>
    <arm_group_label>fiducial markers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IGRT Associated With IMRT</intervention_name>
    <arm_group_label>CBCT</arm_group_label>
    <arm_group_label>fiducial markers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male &gt; 18 years

          -  carcinoma of the prostate histologically confirmed

          -  OMS 0-1

          -  localized stage

          -  favorable, intermediate and unfavorable groups according to NCCN or D'Amico
             classification

          -  patients must have signed a written informed consent form

          -  patients must be affiliated to a Social Health Insurance.

        Exclusion Criteria:

          -  metastasis

          -  indication for pelvic radiation

          -  anticoagulant therapy

          -  lateral or bilateral hip replacement

          -  patient receiving an adult protective services

          -  Patient unable to comply with the required medical follow-up for geographic, social or
             psychological reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles CREHANGE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Georges-François Leclerc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Raypilot dosimetry</keyword>
  <keyword>CBCT (cone beam computed tomography)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

